Sign in with your email address username.


[Comment] A sense of excitement for a specific Lp(a)-lowering therapy

The discovery of lipoprotein(a) [Lp(a)] in 1963, followed by a more detailed biochemical characterisation in the 1970s, introduced a dazzling new lipoprotein composed of two components: an apolipoprotein (apo)B-containing low-density lipoprotein (LDL)-like particle, covalently linked to a plasminogen-like glycoprotein apo(a).1 During the next three decades, genetic approaches greatly advanced the understanding of this particle. Lp(a) is subject to tight genetic control, with more than 90% of its variance residing in the LPA gene encoding apo(a).